According to a new survey, some patients with major neurological diseases believe they were not properly diagnosed for more than a year, potentially leading to patient anxiety, unnecessary or inappropriate treatments, delays in appropriate care, and added costs to the global healthcare system. The opinion survey examined the impact of diagnosis delays in the most prominent neurological disorders: Alzheimer’s (AD), Parkinson’s (PD) and Multiple Sclerosis (MS).
The survey, commissioned by GE Healthcare and conducted by Praxis Research, Inc., reflects opinions of physicians and patients in the US, UK, Germany and France. A total of 240 physicians, consisting of hospital and office-based neurologists and psychiatrists (UK-only) participated. A total of 101 patients with Multiple Sclerosis, Parkinson’s disease or Alzheimer’s disease participated.
According to the survey, median times in patient estimates of time to diagnosis from onset of symptoms were seven to 12 months across all disease states. AD was diagnosed fastest, on average (12.7 months), followed by MS (13.6 months) and PD (14.7 months). This time included the time that patients waited (from less than a week to more than a year) before consulting a physician. Physicians who participated in the survey said approximately a third of patients could or should have been diagnosed faster and may suffer unnecessarily as a result of delay.
“It is not acceptable that some patients with progressive neurological disorders have to wait so long before they receive a diagnosis, during which time many face the possibility of receiving the wrong or unnecessary treatment and needing to consult with multiple healthcare professionals, “ said Gabrielle Silver, MD and Head of Neuroscience Marketing at GE Healthcare. “This delay can be stressful to patients, and can also cost the health economy millions of dollars in unnecessary use of resources. Patients and their families should not have to tolerate lengthy delays.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV